Predicting liver outcomes in fatty liver cirrhosis
Part of Digestive system clinical trials.
This study looks at how to predict future outcomes in adults who have fatty-liver disease (NAFLD) that has progressed to cirrhosis. It may help doctors better estimate risk and plan care, using information from liver tests and scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with cirrhosis caused by fatty liver disease (NAFLD)
- Your cirrhosis must be proven by biopsy or by a lab score (Agile F, F4) above a set threshold
- Your fatty liver cause must be supported by biopsy fat, scan results, or (if those scans are lower) having type 2 diabetes and other metabolic risk factors for at least 5 years
- Your liver function must be fairly preserved (MELD score must be 12 or less)
- You must be able to safely have MRI scans (including no major kidney problems that prevent MRI contrast)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with fatty liver disease (NAFLD) and a related condition (NASH) to see how it changes over time. It may help researchers understand who is most likely to worsen and what patterns show up as the disease progresses.
This study is exploring a new way to predict how liver cirrhosis will progress. It may help doctors better understand and manage the condition.
This study follows people with nonalcoholic fatty liver disease to better understand the condition. It uses an MRI scan and collects body samples to help researchers study changes over time.
This study looks at new, non-invasive methods to predict when chronic liver disease might get worse. It could help you and your doctor catch problems early without needing a biopsy or other invasive procedures.
This study looks at how nutrition affects the health of people with liver cirrhosis (scarred liver) and aims to build a tool to predict their outcomes. If you have cirrhosis, joining may help researchers find better ways to support your health.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
Hear when a new NASH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.